Cantor Fitzgerald Comments on Cabaletta Bio FY2025 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Cabaletta Bio in a research report issued to clients and investors on Tuesday, November 11th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($2.00) per share for the year, down from their previous estimate of ($1.84). Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. Cantor Fitzgerald also issued estimates for Cabaletta Bio’s FY2026 earnings at ($1.17) EPS.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.05.

CABA has been the topic of several other research reports. Jefferies Financial Group started coverage on Cabaletta Bio in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Cabaletta Bio in a report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.11.

Cabaletta Bio Trading Down 3.3%

Shares of Cabaletta Bio stock traded down $0.08 during trading on Thursday, reaching $2.37. The stock had a trading volume of 353,263 shares, compared to its average volume of 2,218,851. The company has a market capitalization of $228.14 million, a price-to-earnings ratio of -0.94 and a beta of 3.10. The stock has a fifty day moving average price of $2.40 and a two-hundred day moving average price of $1.91. Cabaletta Bio has a 52 week low of $0.99 and a 52 week high of $5.46.

Institutional Trading of Cabaletta Bio

A number of hedge funds have recently made changes to their positions in CABA. Bain Capital Life Sciences Investors LLC boosted its position in Cabaletta Bio by 250.5% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock valued at $14,709,000 after acquiring an additional 6,916,237 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Cabaletta Bio by 142.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock worth $13,421,000 after purchasing an additional 5,195,285 shares in the last quarter. Jennison Associates LLC lifted its stake in Cabaletta Bio by 147.4% in the second quarter. Jennison Associates LLC now owns 6,020,167 shares of the company’s stock valued at $9,151,000 after buying an additional 3,586,439 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of Cabaletta Bio during the 2nd quarter worth approximately $3,036,000. Finally, Vanguard Group Inc. grew its position in shares of Cabaletta Bio by 21.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company’s stock worth $9,806,000 after buying an additional 740,032 shares during the period.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.